Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8478708 | 0.98 | SLC6A4 (0.53) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL18662772 | 0.95 | SLC6A4 (0.52) | SLC6A4SLC6A3 | |
| SCHEMBL1492744 | 0.93 | SLC6A4 (0.48) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL18742808 | 0.91 | SLC6A4 (0.47) | SLC6A4SLC6A3 | |
| SCHEMBL668905 | 0.88 | SLC6A4 (0.47) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL1919156 | 0.86 | SLC6A4 (0.45) | SLC6A4SLC6A3 | |
| SCHEMBL17680402 | 0.82 | SLC6A4 (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL14292202 | 0.79 | ALDH1A1 (0.64) | — | |
| SCHEMBL1057221 | 0.78 | DRD2 (0.60) | SLC6A4SLC6A3 | |
| SCHEMBL8155581 | 0.78 | ALDH1A1 (0.41) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | SLC6A4 3748/4885SLC6A3 3549/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | SLC6A4 3748/4885SLC6A3 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.